Drugs / HAT1
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03059693 | Feb → Jun 2016 | atopic eczema | Haus Bioceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT03069144 | Jan → Apr 2012 | psoriasis | Haus Bioceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03848806 | Feb → Jul 2016 | psoriasis | Haus Bioceuticals | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03406117 | Apr → Jun 2016 | atopic eczema, psoriasis | Haus Bioceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HAT1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03059693 ↗ |
| Route | Topical | “developed a topical treatment for eczema/atopic dermatitis (AD) denoted HAT1” NCT03059693 ↗ |